Q2 2026 Quest Diagnostics Inc Earnings Call Transcript

Jul 23, 2026 / 12:30 PM GMT

Release Date Price: €199.3 (+8.40%)

Transcript 10-Q8-K

Key Points

Positve

Quest Diagnostics Inc (DGX) reported a strong revenue growth of over 10% in the second quarter, driven by broad clinical demand and increased volume from collaborations with Corewell Health and Fresenius Medical Care.
The company achieved a 19% increase in adjusted diluted earnings per share, showcasing strong financial performance.
Quest Diagnostics Inc (DGX) is leveraging automation and AI to improve quality and productivity, enhancing customer engagement and insights from lab data.
The company is expanding its reach in the physician channel, delivering high single-digit revenue growth through clinical innovations and increased business with existing customers.
Quest Diagnostics Inc (DGX) is experiencing robust growth in consumer health, with QuestHealth.com generating strong revenue growth and demand for wellness panels and new services.

Negative

Total revenue per requisition decreased by 2.8% compared to the prior year due to the business mix from Corewell and Fresenius.
Operating income as a percentage of revenues was impacted by investments in Project NOVA and the lower operating margin rate associated with the ramp of the Corwell CoLab business.
Higher supplemental deferred compensation expenses adversely impacted operating income.
The company anticipates increased NOVA expenses and higher fuel costs in the second half of 2026, which could affect margins.
There is a potential 30 basis point impact on revenue from ACA exchange subsidy expiration, which could affect future financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DGX.N - Quest Diagnostics Inc
Q2 2026 Quest Diagnostics Inc Earnings Call
Jul 23, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------
Welcome to the Quest Diagnostics Second Quarter 2026 Conference Call.

At the request of the company, this call is being recorded.

The entire contents of the call, including the presentation and the question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved.

Any redistribution, retransmission, or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited.

I'd now like to introduce Dan Hammerley, Vice President of Finance for Quest Diagnostics. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.